Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 3
2005 1
2007 2
2008 3
2009 2
2010 2
2011 1
2012 1
2013 2
2014 4
2016 2
2017 1
2018 1
2019 1
2021 1
2022 1
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Results by year

Filters applied: . Clear all
Page 1
Chimeric antigen receptor T cells to target CD79b in B-cell lymphomas.
Chu F, Cao J, Liu J, Yang H, Davis TJ, Kuang SQ, Cheng X, Zhang Z, Karri S, Vien LT, Bover L, Sun R, Vega F, Green M, Davis RE, Neelapu SS. Chu F, et al. J Immunother Cancer. 2023 Nov 24;11(11):e007515. doi: 10.1136/jitc-2023-007515. J Immunother Cancer. 2023. PMID: 38007239 Free PMC article.
Versatile CAR T-cells for cancer immunotherapy.
Chu F, Cao J, Neelalpu SS. Chu F, et al. Contemp Oncol (Pozn). 2018 Mar;22(1A):73-80. doi: 10.5114/wo.2018.73892. Epub 2018 Mar 5. Contemp Oncol (Pozn). 2018. PMID: 29628798 Free PMC article. Review.
Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment.
Liu S, Xie SM, Liu W, Gagea M, Hanker AB, Nguyen N, Singareeka Raghavendra A, Yang-Kolodji G, Chu F, Neelapu SS, Marchese A, Hanash S, Zimmermann J, Arteaga CL, Tripathy D. Liu S, et al. Among authors: chu f. Breast Cancer Res. 2023 Jun 6;25(1):62. doi: 10.1186/s13058-023-01665-w. Breast Cancer Res. 2023. PMID: 37280713 Free PMC article.
Safety and activity of pembrolizumab in combination with rituximab in relapsed or refractory follicular lymphoma.
Nastoupil LJ, Chin CK, Westin JR, Fowler NH, Samaniego F, Cheng X, Ma MCJ, Wang Z, Chu F, Dsouza L, Obi C, Mims J, Feng L, Zhou S, Green M, Davis RE, Neelapu SS. Nastoupil LJ, et al. Among authors: chu f. Blood Adv. 2022 Feb 22;6(4):1143-1151. doi: 10.1182/bloodadvances.2021006240. Blood Adv. 2022. PMID: 35015819 Free PMC article. Clinical Trial.
CXCR5+CD8+ T cells are a distinct functional subset with an antitumor activity.
Chu F, Li HS, Liu X, Cao J, Ma W, Ma Y, Weng J, Zhu Z, Cheng X, Wang Z, Liu J, Jiang ZY, Luong AU, Peng W, Wang J, Balakrishnan K, Yee C, Dong C, Davis RE, Watowich SS, Neelapu SS. Chu F, et al. Leukemia. 2019 Nov;33(11):2640-2653. doi: 10.1038/s41375-019-0464-2. Epub 2019 Apr 25. Leukemia. 2019. PMID: 31028278 Free PMC article.
CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel.
Plaks V, Rossi JM, Chou J, Wang L, Poddar S, Han G, Wang Z, Kuang SQ, Chu F, Davis RE, Vega F, Bashir Z, Jacobson CA, Locke FL, Reagan PM, Rodig SJ, Lekakis LJ, Flinn IW, Miklos DB, Bot A, Neelapu SS. Plaks V, et al. Among authors: chu f. Blood. 2021 Sep 23;138(12):1081-1085. doi: 10.1182/blood.2021010930. Blood. 2021. PMID: 34041526 Free PMC article. Clinical Trial. No abstract available.
Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment.
Liu S, Xie SM, Liu W, Gagea M, Hanker AB, Nguyen N, Raghavendra AS, Yang-Kolodji G, Chu F, Neelapu SS, Hanash S, Zimmermann J, Arteaga CL, Tripathy D. Liu S, et al. Among authors: chu f. Res Sq [Preprint]. 2023 Feb 14:rs.3.rs-2388864. doi: 10.21203/rs.3.rs-2388864/v1. Res Sq. 2023. PMID: 36824840 Free PMC article. Updated. Preprint.
30 results